Betahistine: Uses, Dosage & Side Effects
A histamine analogue prescribed for the treatment of Meniere's disease, reducing vertigo episodes, tinnitus, and hearing loss by improving inner ear circulation
Betahistine is a histamine analogue medication primarily prescribed for the treatment of Meniere's disease, a chronic condition of the inner ear characterized by recurrent episodes of vertigo (a spinning sensation), tinnitus (ringing or buzzing in the ears), and progressive sensorineural hearing loss. By improving microcirculation in the inner ear and reducing endolymphatic pressure, betahistine helps decrease the frequency and severity of vertigo attacks. It is widely used across Europe, Asia, and Australia, though it is not approved by the FDA in the United States.
Quick Facts: Betahistine
Key Takeaways
- Betahistine is the most widely prescribed medication for Meniere's disease worldwide, helping to reduce the frequency and severity of vertigo attacks, tinnitus, and associated hearing loss.
- The medication works by acting as a partial histamine H1 receptor agonist and H3 receptor antagonist, improving blood flow in the inner ear and reducing excess endolymphatic fluid pressure.
- Improvement is typically noticed after approximately two weeks, but full therapeutic benefit requires several months of continuous treatment at the prescribed dose.
- Taking betahistine with or after food significantly reduces the most common side effects of nausea and indigestion; the tablet should be swallowed whole with water.
- Betahistine is contraindicated in patients with pheochromocytoma (adrenal gland tumor) and should be used with caution in patients with peptic ulcer disease, asthma, or allergic conditions.
What Is Betahistine and What Is It Used For?
Betahistine dihydrochloride is a synthetic analogue of the naturally occurring neurotransmitter histamine. It belongs to the pharmacological class of anti-vertigo preparations (ATC code N07CA01) and has been used clinically for the management of vestibular disorders since the 1960s. Today, betahistine is one of the most commonly prescribed medications for Meniere's disease in Europe, Asia, and Australia, with millions of prescriptions written annually worldwide.
Meniere's disease is a chronic disorder of the inner ear that affects approximately 50 to 200 per 100,000 people globally. The condition is characterized by a triad of debilitating symptoms: episodic vertigo (intense spinning sensation lasting 20 minutes to several hours), fluctuating sensorineural hearing loss (typically affecting low frequencies initially), and tinnitus (persistent ringing, buzzing, or roaring sounds in the affected ear). Many patients also experience a sensation of fullness or pressure in the ear (aural fullness). These symptoms arise from an abnormal accumulation of fluid (endolymph) in the membranous labyrinth of the inner ear, a condition known as endolymphatic hydrops.
Betahistine exerts its therapeutic effects through a dual mechanism of action involving two types of histamine receptors. As a partial agonist at histamine H1 receptors, it causes vasodilation of the precapillary sphincters in the microvasculature of the stria vascularis of the cochlea and the vestibular apparatus. This improves local blood flow and oxygen delivery to the inner ear, which is thought to help normalize the production and absorption of endolymph. Simultaneously, as a potent antagonist at histamine H3 receptors, betahistine inhibits the presynaptic autoreceptors that normally suppress histamine release. This increases histamine turnover in the vestibular nuclei of the brainstem, which facilitates vestibular compensation — the brain's ability to adapt to and recover from vestibular dysfunction.
Clinical studies have demonstrated that betahistine can reduce the frequency of vertigo attacks by 70–90% in many patients when used at adequate doses over a sustained period. The Cochrane Collaboration has reviewed the available evidence and, while noting methodological limitations in some older trials, acknowledges that betahistine is widely used with a generally favorable benefit-risk profile. The European Academy of Otology and Neurotology (EAONO) and the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) both recognize betahistine as a treatment option for Meniere's disease in their clinical practice guidelines.
It is important to note that betahistine is not approved by the U.S. Food and Drug Administration (FDA) and is therefore not commercially available in the United States. This is largely a historical regulatory matter rather than a reflection of safety concerns. Betahistine has been used safely for over 50 years in many countries, and its safety profile is well established through extensive post-marketing surveillance. In some countries, betahistine has also been investigated for the treatment of other vestibular conditions such as benign paroxysmal positional vertigo (BPPV) and vestibular neuritis, although Meniere's disease remains the primary licensed indication.
What Should You Know Before Taking Betahistine?
Contraindications
There are specific situations in which betahistine must not be used. Understanding these absolute contraindications is critical for patient safety. You should not take betahistine if:
- Allergy to betahistine: If you are allergic (hypersensitive) to betahistine dihydrochloride or any of the other ingredients in the tablets (such as citric acid, microcrystalline cellulose, mannitol, colloidal anhydrous silica, or talc), you must not take this medication. Signs of an allergic reaction include skin rash, itching, swelling of the face or throat, and difficulty breathing.
- Pheochromocytoma: If you have a pheochromocytoma, a rare tumor of the adrenal gland that produces excess catecholamines (adrenaline and noradrenaline), betahistine is absolutely contraindicated. Because betahistine is a histamine analogue, it may trigger dangerous catecholamine release from the tumor, potentially causing hypertensive crisis, which can be life-threatening.
Warnings and Precautions
Betahistine requires careful consideration and medical supervision in several clinical situations. Speak with your doctor, pharmacist, or nurse before taking betahistine if any of the following apply to you:
- Peptic ulcer disease: If you have an active peptic ulcer or a history of gastric or duodenal ulcers, betahistine should be used with caution. As a histamine analogue, it may stimulate gastric acid secretion through activation of H2 receptors in the stomach, potentially worsening or reactivating ulcer disease. Your doctor may prescribe gastroprotective medication concurrently.
- Bronchial asthma: Histamine can cause bronchoconstriction in susceptible individuals. Although betahistine acts primarily through H1 and H3 receptors rather than direct mast cell degranulation, patients with bronchial asthma should be monitored carefully during treatment, and the medication should be discontinued if respiratory symptoms worsen.
- Urticaria, skin rash, or allergic rhinitis: Patients with a history of allergic conditions such as chronic urticaria (hives), eczematous skin rashes, or allergic rhinitis (hay fever) may be more susceptible to hypersensitivity reactions. Close monitoring is recommended during the initial phase of treatment.
- Hypotension (low blood pressure): Betahistine may cause mild vasodilation, which can lower blood pressure. Patients with very low blood pressure or those taking antihypertensive medications should be monitored, particularly when starting treatment or adjusting doses.
- Hepatic impairment: Betahistine is extensively metabolized in the liver. Patients with reduced liver function may experience altered drug metabolism and should use betahistine with caution under medical supervision. Dose adjustments may be necessary.
- Renal impairment: The metabolites of betahistine are primarily excreted through the kidneys. Patients with impaired kidney function should use the medication cautiously, and their doctor may need to adjust the dose or monitor kidney function parameters regularly.
Betahistine is not recommended for use in children and adolescents under 18 years of age due to insufficient data on safety and efficacy in these age groups. Meniere's disease is extremely rare in the pediatric population, and alternative diagnostic considerations should be explored in children presenting with vestibular symptoms.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, are planning to become pregnant, or are breastfeeding, consult your doctor or pharmacist before taking betahistine. There are limited clinical data on the use of betahistine during human pregnancy. Animal reproductive toxicity studies have not indicated direct or indirect harmful effects, but as a precautionary measure, betahistine should not be used during pregnancy unless your doctor determines that the potential benefit clearly outweighs any theoretical risk to the developing fetus.
It is not known whether betahistine or its metabolites are excreted in human breast milk. Because of this uncertainty, breastfeeding is not recommended during betahistine treatment unless specifically advised by your prescribing physician. If treatment is deemed essential, your doctor will help you weigh the benefits of breastfeeding against the potential risks to the infant.
Driving and Operating Machinery
No specific studies have been conducted on the effect of betahistine on the ability to drive or operate machinery. Based on its pharmacological profile, betahistine is not expected to impair driving ability or the operation of machinery. However, it is important to note that betahistine may occasionally cause drowsiness as a side effect, and the underlying condition being treated (Meniere's disease) itself causes vertigo and balance disturbances that can significantly impair driving safety.
You are personally responsible for assessing whether you are fit to drive a vehicle or perform tasks that require alertness. One of the factors that may affect your ability is the use of medication due to its effects and side effects. Patients should assess their own fitness to drive, taking into account both the effects of the medication and their vestibular symptoms. If you feel drowsy or dizzy, do not drive or operate heavy machinery. Discuss any concerns with your doctor or pharmacist.
How Does Betahistine Interact with Other Drugs?
Betahistine has a relatively limited drug interaction profile compared to many other medications. However, certain interactions are clinically relevant and must be considered to ensure safe and effective treatment. The pharmacological basis for these interactions relates primarily to betahistine's mechanism as a histamine analogue and the enzymatic pathways involved in its metabolism.
Betahistine is rapidly and completely absorbed after oral administration and is primarily metabolized by the enzymes monoamine oxidase (MAO) and diamine oxidase (DAO) in the liver, intestinal wall, and other tissues. Its principal metabolite, 2-pyridylacetic acid, is pharmacologically inactive and is excreted by the kidneys. This metabolic pathway is the basis for the most important drug interactions described below.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| MAO inhibitors (e.g., selegiline, phenelzine, tranylcypromine, rasagiline) | MAO inhibitors block the primary metabolic pathway of betahistine (monoamine oxidase), potentially leading to elevated plasma levels and increased pharmacological activity of betahistine. | Use with caution under close medical supervision. Your doctor may need to reduce the betahistine dose or monitor you more closely for side effects. Do not start or stop MAO inhibitors without consulting your doctor. |
| Antihistamines (e.g., cetirizine, loratadine, diphenhydramine, chlorpheniramine, fexofenadine) | Antihistamines block histamine receptors, which directly opposes the therapeutic mechanism of betahistine (a histamine H1 agonist and H3 antagonist). Concurrent use may reduce the clinical effectiveness of betahistine. | Avoid concurrent use if possible. If antihistamines are necessary for allergy treatment, consult your doctor about alternative approaches or timing strategies to minimize the interaction. |
Minor Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| H2 receptor blockers (e.g., famotidine, ranitidine, cimetidine) | Theoretical interaction as both drugs affect histamine receptor signaling, though through different receptor subtypes. Clinical significance is considered low. | Generally safe to use together. Inform your doctor if you are taking H2 blockers for acid reflux or stomach ulcers. |
| Beta-blockers (e.g., propranolol, atenolol, metoprolol) | Both betahistine and some beta-blockers can affect blood pressure. Additive hypotensive effects are theoretically possible, particularly with vasodilating beta-blockers. | Monitor blood pressure when starting betahistine in patients already taking beta-blockers. Report any dizziness, lightheadedness, or fainting to your doctor. |
| Proton pump inhibitors (e.g., omeprazole, pantoprazole, lansoprazole) | No direct pharmacokinetic interaction. Both drugs may affect gastric pH, but through different mechanisms. | Safe to use together. Proton pump inhibitors may actually be beneficial for patients who experience gastrointestinal side effects from betahistine. |
Betahistine should be taken with or immediately after a meal. Food does not significantly affect the total absorption of betahistine, but taking it with food delays absorption slightly, which reduces peak plasma concentrations and thereby minimizes the risk of gastrointestinal side effects such as nausea and indigestion. This is the recommended way to take betahistine for optimal tolerability.
In vitro studies suggest that betahistine does not inhibit or induce the major cytochrome P450 enzyme systems (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4), which means it is unlikely to affect the metabolism of most other commonly prescribed medications processed through these pathways. This gives betahistine a relatively clean interaction profile compared to many other neurological medications.
Nevertheless, it is always important to inform your doctor or pharmacist about all medications you are taking, including over-the-counter medicines, herbal preparations, and dietary supplements, before starting betahistine. This allows your healthcare provider to assess the full picture and adjust treatment as necessary.
What Is the Correct Dosage of Betahistine?
Betahistine dosage should always be determined by your prescribing physician and tailored to your individual response and tolerance. The following information represents standard dosing recommendations based on approved product information from the European Medicines Agency (EMA) and international clinical guidelines. Always take this medication exactly as your doctor or pharmacist has instructed.
Adults
Standard Oral Dosing
Daily dose range: 24 to 48 mg per day
Typical starting dose: 8 mg or 16 mg, two to three times daily
Administration: Take with or immediately after food, swallowed whole with water
16 mg tablets: Can be split in half along the score line if a lower dose is needed
Treatment duration: Treatment is long-term. Improvement may be noticed after approximately two weeks, but optimal results typically require several months of continuous use. Do not stop treatment without consulting your doctor.
The dosing schedule is flexible and can be adjusted by your doctor based on your response to treatment. Some patients respond well to 24 mg daily (for example, 8 mg three times daily), while others may require the higher end of the dose range at 48 mg daily (for example, 16 mg three times daily or 24 mg twice daily). Your doctor will determine the most appropriate dose for you and may adjust it over time based on symptom control and tolerability.
In clinical practice, some specialists have used higher doses up to 48 mg three times daily (144 mg/day) for refractory cases, as investigated in the large-scale BEMED trial (Adrion et al., BMJ 2016). However, doses above 48 mg/day exceed the standard licensed dose range in most countries and should only be undertaken under specialist supervision with careful monitoring for adverse effects.
Children and Adolescents
Betahistine is not recommended for use in children and adolescents under 18 years of age. There are insufficient data on the safety and effectiveness of betahistine in the pediatric population. Meniere's disease is very rare in children, and vestibular symptoms in this age group usually have different underlying causes that require separate diagnostic evaluation and management.
Elderly Patients
There is limited specific data on the use of betahistine in elderly patients, although Meniere's disease is most prevalent in the 40–60 age group and many patients continue treatment well into older age. Betahistine should be used with caution in patients over 65 years of age. Elderly patients may be more susceptible to the gastrointestinal and hypotensive side effects of betahistine due to age-related changes in hepatic metabolism, renal excretion, and cardiovascular regulation. Kidney and liver function should be assessed before starting treatment, and dosing may need to be adjusted accordingly. Regular monitoring is recommended, particularly in the initial weeks of treatment.
Hepatic and Renal Impairment
Patients with hepatic (liver) impairment should use betahistine with caution. Since the drug is primarily metabolized by monoamine oxidase and diamine oxidase in the liver and intestinal wall, reduced liver function may result in slower metabolism and higher plasma concentrations. Your doctor may need to reduce the dose or extend the interval between doses. Similarly, patients with renal (kidney) impairment should be monitored, as the inactive metabolite 2-pyridylacetic acid is excreted through the kidneys. Reduced kidney function may lead to accumulation of metabolites. Dose adjustments should be made based on individual clinical assessment and, where available, monitoring of renal function parameters.
Missed Dose
If you forget to take a dose of betahistine, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a forgotten dose. Consistent daily dosing is important for the effectiveness of betahistine, so try to take your tablets at the same times each day to help establish a routine. If you frequently forget doses, consider using a pill organizer or setting reminder alarms.
Overdose
If you have taken more betahistine than prescribed, or if a child has accidentally ingested the medication, contact your local emergency services or poison control center immediately for assessment and advice.
Very few cases of betahistine overdose have been reported in the medical literature, and in the majority of reported cases, no serious adverse effects were observed. Patients who experienced overdose recovered fully in all documented cases. Potential symptoms of significant overdose may include headache, facial flushing, dizziness, rapid heart rate (tachycardia), low blood pressure (hypotension), breathing difficulties (bronchospasm), and swelling of the upper airways.
Treatment of overdose is supportive and symptomatic. There is no specific antidote for betahistine. In the event of a recent substantial overdose, gastric lavage (stomach washout) or activated charcoal may be considered if the patient presents within one to two hours of ingestion. Vital signs should be monitored, and supportive care provided as needed. Given the short half-life of betahistine (approximately 3.5 hours), symptoms of overdose would be expected to resolve relatively quickly.
What Are the Side Effects of Betahistine?
Like all medicines, betahistine can cause side effects, although not everybody experiences them. The majority of patients tolerate betahistine well, particularly when it is taken with or after food as recommended. The side effect profile of betahistine is generally considered favorable compared to many other neurological medications, which is one reason it remains a first-line treatment option for Meniere's disease in many countries.
The following classification of side effects is based on international pharmacovigilance data from the European Medicines Agency (EMA) and approved product information. Side effects are grouped by frequency to help you understand how likely they are to occur.
Common
- Nausea: Feeling of sickness, usually mild and transient. Significantly reduced by taking betahistine with or immediately after food.
- Dyspepsia: Indigestion, stomach discomfort, or a feeling of fullness after eating. Taking the medication with food helps prevent this effect.
- Headache: Mild to moderate headache has been reported by some patients, particularly during the initial weeks of treatment.
Frequency Not Known
- Mild gastrointestinal complaints: Vomiting, abdominal pain, bloating, and flatulence have been reported. These effects are generally mild and often improve with continued treatment, particularly when the medication is taken with meals.
- Drowsiness: Some patients have reported feeling sleepy or drowsy, particularly at higher doses or during the initial phase of treatment. This may affect your ability to drive or operate machinery.
- Skin hypersensitivity reactions: Hives (urticaria), skin rash, and itching (pruritus) have been reported in some patients. These reactions are usually mild and resolve upon discontinuation of the medication.
Serious (Very Rare)
- Anaphylaxis: Severe whole-body allergic reaction with potential drop in blood pressure, difficulty breathing, rapid heartbeat, and loss of consciousness. Requires immediate emergency treatment with epinephrine.
- Angioedema: Swelling of the face, lips, tongue, or throat (angioneurotic edema), which can obstruct the airway and be life-threatening. Seek emergency medical attention immediately if this occurs.
Stop taking betahistine and call emergency services immediately if you experience any of the following: sudden swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; severe skin rash or hives spreading rapidly over the body; feeling faint or experiencing a sudden drop in blood pressure; or severe wheezing or chest tightness. These may be signs of a serious allergic reaction (anaphylaxis) that requires urgent treatment.
The gastrointestinal side effects of betahistine are the most commonly reported and are largely preventable by taking the medication with food. This simple measure substantially reduces the incidence and severity of nausea and stomach discomfort. If gastrointestinal symptoms persist despite taking betahistine with meals, your doctor may recommend a temporary dose reduction or the addition of a gastroprotective medication such as a proton pump inhibitor.
If you experience any side effects not listed here, or if any of the listed side effects become severe or persistent, contact your doctor or pharmacist. You can also report suspected side effects to your national pharmacovigilance authority, such as the MHRA Yellow Card Scheme (UK), the EMA EudraVigilance system (EU), or equivalent agencies in your country. Reporting side effects helps regulatory authorities continuously monitor the safety profile of medications and identify any previously unknown adverse reactions.
How Should You Store Betahistine?
Proper storage of betahistine ensures that the medication remains effective and safe throughout its shelf life. The following storage guidelines apply to all betahistine tablet formulations unless the specific product packaging states otherwise:
- Temperature: No special temperature requirements are specified for betahistine tablets. Store at normal room temperature (typically below 25°C / 77°F). Avoid exposure to excessive heat, direct sunlight, or freezing temperatures.
- Packaging: Keep the tablets in their original blister packs (PVC/PVdC/aluminum foil blisters) or HDPE bottles with the cap securely closed. This protects them from moisture and maintains their quality throughout the shelf life.
- Child safety: Keep all medicines out of the sight and reach of children. Store medicines in a locked cabinet or high shelf where children cannot access them. Accidental ingestion by children should be treated as a potential emergency; contact your local poison control center or emergency services for advice immediately.
- Expiry date: Do not use betahistine after the expiry date printed on the carton or container after “EXP.” The expiry date refers to the last day of that month. Check the expiry date before each use and discard any expired medication properly.
- Disposal: Do not throw away any medicines via wastewater or household waste. Return unused or expired betahistine tablets to your pharmacy for environmentally safe disposal. These measures help protect the environment from pharmaceutical contamination of water supplies and soil.
Betahistine tablets are available in both blister packs and HDPE (high-density polyethylene) bottles. Common pack sizes include 20, 30, 50, 60, 100, and 120 tablets, though not all sizes may be marketed in your country. Both packaging types provide adequate protection for the tablets under normal storage conditions. If you notice any change in the appearance, color, or smell of the tablets, do not use them and consult your pharmacist for replacement.
What Does Betahistine Contain?
Betahistine tablets contain betahistine dihydrochloride as the active pharmaceutical ingredient. The inactive ingredients (excipients) serve various functions in the formulation, including binding the tablet, aiding disintegration, improving flowability during manufacturing, and ensuring consistent drug release. Understanding the full ingredient list is important for patients with known allergies or sensitivities to specific excipients.
Active Ingredient
Betahistine dihydrochloride: Each tablet contains either 8 mg or 16 mg of betahistine dihydrochloride. This is a white to off-white crystalline powder that is freely soluble in water. Its chemical name is N-alpha-methyl-2-pyridylethanamine dihydrochloride, with a molecular weight of 209.12 g/mol. Betahistine dihydrochloride is the salt form used in pharmaceutical preparations because of its superior stability and water solubility compared to the free base.
Inactive Ingredients (Excipients)
The following inactive ingredients are present in betahistine tablets and serve specific pharmaceutical functions:
- Citric acid: Acts as a pH modifier and contributes to tablet stability and disintegration. It helps create an optimal environment for drug dissolution.
- Microcrystalline cellulose: A purified, partially depolymerized cellulose that serves as a binder and filler. It provides structural integrity to the tablet and helps ensure uniform drug distribution.
- Mannitol: A sugar alcohol used as a diluent and sweetening agent. It is non-cariogenic (does not promote tooth decay) and has excellent compressibility properties for tablet manufacturing.
- Colloidal anhydrous silica: An anti-caking and flow agent (also called colloidal silicon dioxide) that improves the flow properties of the powder blend during tablet compression, ensuring consistent weight and drug content in each tablet.
- Talc: A lubricant that prevents the tablet from sticking to the manufacturing equipment during compression and helps in smooth swallowing of the tablet.
Tablet Appearance
Betahistine tablets are white, round, and uncoated. The 8 mg tablets are flat with smooth surfaces on both sides and have a diameter of approximately 7 mm. The 16 mg tablets are biconvex (slightly rounded on both sides) with a score line on one side and the letter “I” embossed on each side of the score, with a smooth reverse side and a diameter of approximately 8.7 mm. The score line on the 16 mg tablets allows them to be divided into two equal halves for dose adjustment.
Betahistine tablets do not contain gluten, lactose, sucrose, gelatin, or any animal-derived ingredients. This makes them suitable for patients with celiac disease, lactose intolerance, and those following vegetarian or vegan diets. However, if you have any specific allergies or dietary restrictions, always check the patient information leaflet supplied with your specific product or consult your pharmacist for confirmation.
Frequently Asked Questions About Betahistine
Betahistine is primarily used to treat Meniere's disease, a chronic inner ear condition causing recurrent vertigo (spinning sensation), tinnitus (ringing in the ears), and progressive hearing loss. It works by improving blood circulation in the inner ear and reducing excess endolymphatic fluid pressure. Betahistine is one of the most widely prescribed medications for Meniere's disease worldwide, used across Europe, Asia, and Australia. It may also be prescribed off-label for other vestibular disorders, although Meniere's disease remains the primary approved indication.
Improvement in symptoms may be noticed after approximately two weeks of continuous treatment. However, the full therapeutic benefit of betahistine typically requires several months of regular use at the prescribed dose. Treatment is long-term, and patients should not stop taking betahistine without consulting their doctor, even if symptoms improve, as this could lead to recurrence of vertigo attacks. Some patients may notice a gradual reduction in the frequency and severity of episodes over the first three to six months of treatment.
The most common side effects are nausea, indigestion (dyspepsia), and headache, which may affect up to 1 in 10 users. These are usually mild and can be significantly reduced by taking betahistine with or immediately after food. Serious side effects such as severe allergic reactions (anaphylaxis) or swelling of the face and throat (angioedema) are extremely rare but require immediate medical attention if they occur. Most patients tolerate betahistine well with minimal side effects.
Betahistine should not be taken during pregnancy unless your doctor has determined it is absolutely necessary and the potential benefit outweighs any theoretical risk. There is limited clinical data on the use of betahistine in pregnant women. Similarly, it is not known whether betahistine passes into breast milk, so breastfeeding is not recommended during treatment unless specifically advised by your physician. Always consult your healthcare provider before taking any medication during pregnancy or breastfeeding.
The most significant drug interactions involve MAO inhibitors (used for depression or Parkinson's disease), which can increase betahistine levels in the blood, and antihistamines (allergy medications such as cetirizine or loratadine), which may reduce betahistine's effectiveness by blocking the same receptor pathways. Betahistine has a relatively clean interaction profile compared to many other neurological medications. Always inform your doctor about all medications, supplements, and herbal remedies you are taking before starting betahistine treatment.
Betahistine is not approved by the U.S. Food and Drug Administration (FDA) and is not commercially available in the United States. This is largely a historical regulatory matter rather than a reflection of safety or efficacy concerns. Betahistine has been used safely for over 50 years in many countries worldwide, including throughout the European Union, the United Kingdom, Australia, Japan, and many countries in Asia and Latin America. In the US, some patients obtain betahistine through compounding pharmacies with a doctor's prescription.
References
The information in this article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- European Medicines Agency (EMA). Betahistine – Summary of Product Characteristics (SmPC). European public assessment report. Available at: www.ema.europa.eu
- James AL, Burton MJ. Betahistine for Meniere's disease or syndrome. Cochrane Database of Systematic Reviews. 2001;(1):CD001873. doi:10.1002/14651858.CD001873
- Adrion C, Fischer CS, Wagner J, et al. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial). BMJ. 2016;352:h6816. doi:10.1136/bmj.h6816
- Lacour M, van de Heyning PH, Novotny M, Tighilet B. Betahistine in the treatment of Meniere's disease. Neuropsychiatric Disease and Treatment. 2007;3(4):429-440.
- British National Formulary (BNF). Betahistine dihydrochloride: indications, dose, contra-indications, side-effects. NICE. Available at: bnf.nice.org.uk
- Murdin L, Hussain K, Schilder AG. Betahistine for symptoms of vertigo. Cochrane Database of Systematic Reviews. 2016;(6):CD010696. doi:10.1002/14651858.CD010696.pub2
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd list, 2023. Geneva: World Health Organization.
- Strupp M, Zwergal A, Brandt T. Episodic ataxia type 2. Neurotherapeutics. 2007;4(2):267-273.
- National Institute for Health and Care Excellence (NICE). Meniere's disease: assessment and management. Clinical Knowledge Summaries. Available at: cks.nice.org.uk
- van de Heyning PH, Muehlmeier G, Cox T. Efficacy and safety of betahistine in patients with Meniere's disease: a systematic review. Audiology and Neurotology. 2011;16(6):413-424. doi:10.1159/000324899
About the Medical Editorial Team
All medical content on iMedic is reviewed by qualified healthcare professionals. Our editorial process follows international standards for medical accuracy and readability.
All claims are supported by Level 1A evidence from systematic reviews, meta-analyses, and randomized controlled trials. We follow the GRADE framework for evaluating the certainty of evidence.
Content is reviewed by board-certified specialists in clinical pharmacology and otolaryngology. All information is cross-referenced against current EMA, BNF, and Cochrane guidelines.
Articles are reviewed and updated at least annually, or sooner when new evidence emerges. Last medical review: . First published: .
iMedic receives no commercial funding from pharmaceutical companies. All content is editorially independent with no conflicts of interest or industry sponsorship.